MCC950 sodium
(Synonyms: N-[[(1,2,3,5,6,7-六氢-S-引达省-4-基)氨基]羰基]-4-(1-羟基-1-甲基乙基)-2-呋喃磺酰胺单钠盐,CRID3 sodium salt ) 目录号 : GC10634
MCC950 是一种有效的选择性小分子 NLRP3 抑制剂。
Cas No.:256373-96-3
Sample solution is provided at 25 µL, 10mM.
MCC950 is a potent, selective, small molecule inhibitor of NLRP3. MCC950 blocks canonical and non-canonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibits NLRP3 but not AIM2, NLRC4 or NLRP1 activation. MCC950 reduces Interleukin-1p (IL-1β) production in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Furthermore, MCC950 treatment rescues neonatal lethality in a mouse model of CAPS and is active in ex vivo samples from individuals with Muckle-Wells syndrome. MCC950 is thus a potential therapeutic for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases, and a tool for the further study of the NLRP3 inflammasome in human health and disease.[1]
The half-maximal inhibitory concentration (IC50) of MCC950 in BMDM was approximately 7.5 nM, while in HMDM it had a similar inhibitory capacity (IC50 = 8.1 nM). Cells were first primed with LPS then pre-treated with MCC950 and lastly stimulated with the NLRP3 stimulus ATP. Treating cells with nanomolar concentrations of MCC950 dose dependently inhibited the release of IL-1β in BMDM, HMDM and PBMC. [1]
Mice were pre-treated with MCC950 one hour before i.p. injection of LPS and were assessed two hours later. Pre-treatment with MCC950 reduced serum concentrations of IL-1β and IL-6 while it did not considerably decrease the amount of TNF-α, indicating that MCC950 is active in vivo.Besides, treatment of db/db mice with NLRP3 inflammasome inhibitor MCC950 ameliorated anxiety- and depression-like behaviors as well as cognitive dysfunction, and reversed increased NLRP3, ASC, and IL-1βexpression levels and caspase-1 activity in hippocampus. Moreover, MCC950 treatment significantly improved insulin sensitivity in db/db mice.[1,2]
References:
[1]. Coll, Rebecca C et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature medicine vol. 21,3 (2015): 248-55.
[2]. Zhai, Yadong et al. Inhibiting the NLRP3 Inflammasome Activation with MCC950 Ameliorates Diabetic Encephalopathy in db/db Mice. Molecules (Basel, Switzerland) vol. 23,3 522. 27 Feb. 2018.
MCC950 是一种有效的选择性小分子 NLRP3 抑制剂。 MCC950 在纳摩尔浓度下阻断经典和非经典 NLRP3 激活。 MCC950 特异性抑制 NLRP3，但不抑制 AIM2、NLRC4 或 NLRP1 激活。 MCC950 减少体内白细胞介素-1p (IL-1β) 的产生并减轻实验性自身免疫性脑脊髓炎 (EAE) 的严重程度，EAE 是一种多发性硬化症的疾病模型。此外，MCC950 治疗可挽救 CAPS 小鼠模型中的新生儿致死率，并且在 Muckle-Wells 综合征患者的离体样本中具有活性。因此，MCC950 是一种潜在的治疗 NLRP3 相关综合征（包括自身炎症和自身免疫性疾病）的药物，也是进一步研究 NLRP3 炎性体在人类健康和疾病中的作用的工具。[1]
MCC950 在 BMDM 中的半数最大抑制浓度 (IC50) 约为 7.5 nM，而在 HMDM 中具有相似的抑制能力 (IC50 = 8.1纳米）。细胞首先用 LPS 引发，然后用 MCC950 预处理，最后用 NLRP3 刺激物 ATP 刺激。用纳摩尔浓度的 MCC950 处理细胞会剂量依赖性地抑制 BMDM、HMDM 和 PBMC 中 IL-1β 的释放。 [1]
小鼠在腹腔注射前一小时用 MCC950 进行预处理。注射 LPS 并在两小时后进行评估。用 MCC950 预处理降低了 IL-1β 和 IL-6 的血清浓度，同时没有显着降低 TNF-α 的量，表明 MCC950 在体内具有活性。此外，用 NLRP3 炎性体抑制剂 MCC950 治疗 db/db 小鼠改善了焦虑和抑郁样行为以及认知功能障碍，并逆转了海马中增加的 NLRP3、ASC 和 IL-1β 表达水平和 caspase-1 活性。此外，MCC950 治疗显着改善了 db/db 小鼠的胰岛素敏感性。[1,2]
| Cell experiment [1]: | |
|
Cell lines |
Bone marrow, HEK293T cells |
|
Preparation Method |
MCC950 sodium salt is highly soluble in aqueous solutions |
|
Reaction Conditions |
0.001–10 µM, 30 min |
|
Applications |
The half-maximal inhibitory concentration (IC50) of MCC950 in BMDM was approximately 7.5 nM, while in HMDM it had a similar inhibitory capacity (IC50 = 8.1 nM). |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6 mice |
|
Preparation Method |
MCC950 sodium salt is highly soluble in aqueous solutions. |
|
Dosage form |
50 mg/kg, Intraperitoneal injection |
|
Applications |
MCC950 not only inhibits NLRP3 in vivo and attenuates EAE severity, but also rescues a mouse model of CAPS and inhibits NLRP3 in human MWS cells. |
|
References: [1]. Coll, Rebecca C et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature medicine vol. 21,3 (2015): 248-55. [2]. Zhai, Yadong et al. Inhibiting the NLRP3 Inflammasome Activation with MCC950 Ameliorates Diabetic Encephalopathy in db/db Mice. Molecules (Basel, Switzerland) vol. 23,3 522. 27 Feb. 2018. |
|
| Cas No. | 256373-96-3 | SDF | |
| 别名 | N-[[(1,2,3,5,6,7-六氢-S-引达省-4-基)氨基]羰基]-4-(1-羟基-1-甲基乙基)-2-呋喃磺酰胺单钠盐,CRID3 sodium salt | ||
| 化学名 | sodium ((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((4-(2-hydroxypropan-2-yl)furan-2-yl)sulfonyl)amide | ||
| Canonical SMILES | O=C(NC1=C2CCCC2=CC3=C1CCC3)[N-]S(=O)(C4=CC(C(O)(C)C)=CO4)=O.[Na+] | ||
| 分子式 | C20H23N2NaO5S | 分子量 | 426.5 |
| 溶解度 | ≥ 21.45 mg/mL in DMSO, ≥ 100 mg/mL in Water with gentle warming, ≥ 43 mg/mL in EtOH | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3447 mL | 11.7233 mL | 23.4467 mL |
| 5 mM | 0.4689 mL | 2.3447 mL | 4.6893 mL |
| 10 mM | 0.2345 mL | 1.1723 mL | 2.3447 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
DBP exposure led NLRP3-mediated pyroptosis via the p38MAPK/NF-κB signaling pathway in HepG2 cells.(G) protein expression in HepG2 cells. DBP: 40 μM, SB203580:5 μM, PDTC: 10 μM, MCC950: 10 μM.
Before DBP stimulation, the p38MAPK (SB203580, 5 μM) (GLPBIO USA), NF-κB (PDTC, 10 μM) and NLRP3 (MCC950, 10 μM) (GLPBIO, USA) inhibitors were introduced to the medium 1 h in advance, respectively.
Sci Total Environ (2023): 165500. PMID: 37442457 IF: 9.8003 -
Related Biological Data
MCC950 attenuated apoptosis in AlCl3-treated Parkin-/- mice hippocampus. (B) Effects of MCC950 on the apoptosis of mice hippocampus by TUNEL staining.
The second-time was treated with normal saline, MitoQ (5 mg/kg body weight, twice weekly) or MCC950 (GlpBio) (10 mg/kg body weight, twice weekly) by intraperitoneal injection in the afternoon of the same day.
Ecotox Environ Safe 264 (2023): 115459. PMID: 37703808 IF: 6.7996 -
Related Biological Data
MCC950 reduced the activation of the NLRP3 inflammasome in LPS-induced RAW 264.7 cells.(a) Effects of MCC950 on NLRP3 expression in LPS-induced RAW 264.7 macrophages as determined by Western blot analysis.
Mice in the IMQ + MCC950 group were intra-gastrically administered with MCC950 (GLPBIO, USA) at a dose of 20 mg/kg/d for 7 consecutive days.
Int Immunopharmacol 124 (2023): 110811. PMID: 37647679 IF: 5.5999 -
Related Biological Data
MCC950 reduces susceptibility to Kainic Acid-induced seizures in mice.B-D: Seizure severity (B): Seizure latency (C): and seizure duration (D).
On the fifth day after electrode implantation, MCC950 (10 mg/kg)(GC10634, GlpBio) was intraperitoneally injected into the mice in the MCC950 groups, whereas those in the CT groups received an equal volume of saline intraperitoneally as a vehicle.
Int Immunopharmacol 126 (2024): 111236. PMID: 38039716 IF: 5.5999 -
Related Biological Data
Refractive status and expression levels of NLRP3 signaling pathway-related factors in the three blank control groups of mice. No statistically significant differences were observed in the refractive status (A) and axial length (B) among the age-matched groups of mice.
To prepare the MCC950 injectable solution, solid MCC950 powder ( GLPBIO) was dissolved in freshly prepared saline solution at a concentration of 50 mg/mL.
Int J Mol Sci 24.21 (2023): 15839. PMID: 37958819 IF: 5.5999 -
Related Biological Data
(A–B) Protein levels of NLRP3, caspase-1, and GSDMD-N.
Mice in the HFPO-TA + MCC950 group received intraperitoneal injections of MCC950 (10 mg/kg, twice/week for 4 weeks; GLPBIO, USA).
Food Chem Toxicol (2023): 113706. PMID: 36871880 IF: 5.5716